EnginZyme raises US$9.07M to shift from R&D to commercial biomanufacturing
What's the deal? EnginZyme, a Solna-based biomanufacturing startup, has closed a US$9.07M (roughly $7.6 million) Series C equity round. New shareholders Lotus One Investment and Valquest Partners Europe led the raise and joined the board, with Sofinnova Partners, Industrifonden, Navigare VenturesDealroom has a profile for this one. Try Dealroom →, and Almi Invest GreenTechDealroom has a profile for this one. Try Dealroom → among key participants.
What does it do? The company uses enzymes to make production more cost-efficient and sustainable for the personal care, food, and pharmaceutical industries. Its patented enzyme immobilisation technology enables biomanufacturing without living organisms, promising lower cost in use and a smaller environmental footprint than traditional chemical manufacturing.
Why now? The round marks EnginZyme's shift from research and development to a commercially driven strategy. "With our growth strategy established, closing this new investment round was a priority for enginzyme," said chief executive officer Aymeric de Gantes.
What's the endgame? The new shareholders bring complementary expertise to help EnginZyme deliver biomanufacturing solutions across its three target industries, de Gantes said. The company works with global manufacturers from techno-economic analysis through to industrial production.
The signal: At roughly $7.6 million, the round sits in the smaller tier of venture financings — a modest cheque for a startup moving from the lab toward commercial scale. But the mix of returning and new backers signals continued investor appetite for enzyme-based alternatives to conventional chemical manufacturing.
Read more: onvista.de
Image credit: Montage Communications
